Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Research & Development

Product Pipeline

Targeted Approach To

Rare Diseases

News & Events

September 29, 2017

Proteus Syndrome Phase 1 Data Presentation

ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting

ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

More News & Events »